Europe Nucleic Acid Therapeutics Cdmo Market Size & Outlook
Europe nucleic acid therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Europe nucleic acid therapeutics cdmo market highlights
- The Europe nucleic acid therapeutics cdmo market generated a revenue of USD 3,517.1 million in 2023.
- The market is expected to grow at a CAGR of 13.5% from 2024 to 2030.
- In terms of segment, rna-based therapies was the largest revenue generating type in 2023.
- Gene Therapy is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Germany is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 3,517.1 million |
| Market revenue in 2030 | USD 8,533.6 million |
| Growth rate | 13.5% (CAGR from 2023 to 2030) |
| Largest segment | Rna-based therapies |
| Fastest growing segment | Gene Therapy |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, RNA-based Therapies |
| Key market players worldwide | Catalent Inc, Thermo Fisher Scientific Inc, Lonza Group Ltd, FUJIFILM Holdings Corp, Charles River Laboratories International Inc, Eurofins Scientific SE, PerkinElmer, Oxford Biomedical Research, Danaher Corp |
Other key industry trends
- In terms of revenue, Europe region accounted for 26.0% of the global nucleic acid therapeutics cdmo market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 9,109.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Nucleic Acid Therapeutics CDMO Market Scope
Nucleic Acid Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe nucleic acid therapeutics cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nucleic acid therapeutics cdmo market will help companies and investors design strategic landscapes.
Rna-based therapies was the largest segment with a revenue share of 65.76% in 2023. Horizon Databook has segmented the Europe nucleic acid therapeutics cdmo market based on gene therapy, rna-based therapies covering the revenue growth of each sub-segment from 2018 to 2030.
Europe holds the second-largest share of the global nucleic acid therapeutics CDMO market owing to the presence of reputed pharmaceutical and biotechnology companies in this region.
In addition, there is a large number of CDMOs specializing in therapy innovation in various European countries like the UK, Germany, and France, which is expected to contribute to market growth in this region.
There has also been a growing trend of outsourcing to East European countries, which is also expected to contribute to the increasing demand for nucleic acid therapeutics in this region.
Reasons to subscribe to Europe nucleic acid therapeutics cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe nucleic acid therapeutics cdmo market databook
-
Our clientele includes a mix of nucleic acid therapeutics cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe nucleic acid therapeutics cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Europe nucleic acid therapeutics cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe nucleic acid therapeutics cdmo market size, by country, 2018-2030 (US$M)
Europe Nucleic Acid Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
